Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Development of Focal Segmental Glomerulosclerosis Patient-Reported Outcome Measures: Symptom Diary and Symptom Impact Questionnaire.

Mathias SD, Vallow S, Gipson DS, Thorneloe KS, Sprecher D.

Am J Kidney Dis. 2017 Oct;70(4):532-540. doi: 10.1053/j.ajkd.2017.04.023. Epub 2017 Jun 26.

PMID:
28663063
2.

Development of the Systemic Lupus Erythematosus Steroid Questionnaire (SSQ): a novel patient-reported outcome tool to assess the impact of oral steroid treatment.

Mathias SD, Berry P, De Vries J, Askanase A, Pascoe K, Colwell HH, Chang DJ.

Health Qual Life Outcomes. 2017 Feb 28;15(1):43. doi: 10.1186/s12955-017-0609-9.

3.

Treatment Satisfaction in Systemic Lupus Erythematosus: Development of a Patient-Reported Outcome Measure.

Mathias SD, Berry P, Pascoe K, de Vries J, Askanase AD, Colwell HH, Chang DJ.

J Clin Rheumatol. 2017 Mar;23(2):94-101. doi: 10.1097/RHU.0000000000000495.

PMID:
28225511
4.
5.

The Diabetes Intention, Attitude, and Behavior Questionnaire: evaluation of a brief questionnaire to measure physical activity, dietary control, maintenance of a healthy weight, and psychological antecedents.

Traina SB, Mathias SD, Colwell HH, Crosby RD, Abraham C.

Patient Prefer Adherence. 2016 Feb 29;10:213-22. doi: 10.2147/PPA.S94878. eCollection 2016.

6.

Measurement properties of a patient-reported outcome measure assessing psoriasis severity: The psoriasis symptoms and signs diary.

Mathias SD, Feldman SR, Crosby RD, Colwell HH, McQuarrie K, Han C.

J Dermatolog Treat. 2016 Aug;27(4):322-7. doi: 10.3109/09546634.2015.1114567. Epub 2015 Dec 4.

PMID:
26634943
7.

The minimal important difference for measures of urticaria disease activity: Updated findings.

Mathias SD, Crosby RD, Rosén KE, Zazzali JL.

Allergy Asthma Proc. 2015 Sep-Oct;36(5):394-8. doi: 10.2500/aap.2015.36.3873.

PMID:
26314821
8.

Pragmatic measurement of health satisfaction in people with type 2 diabetes mellitus using the Current Health Satisfaction Questionnaire.

Traina SB, Colwell HH, Crosby RD, Mathias SD.

Patient Relat Outcome Meas. 2015 Mar 26;6:103-15. doi: 10.2147/PROM.S79368. eCollection 2015.

9.

Validation of the Patient Perception of Intensity of Urgency Scale in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia.

Mathias SD, Crosby RD, Nazir J, Klaver M, Drogendijk T, Hakimi Z, Odeyemi IA.

Value Health. 2014 Dec;17(8):823-9. doi: 10.1016/j.jval.2014.09.002. Epub 2014 Nov 6.

10.

Measurement properties of the flu-like symptom index from the hepatitis physical symptom severity diary.

Mathias S, Crosby RD, Bayliss MS, L'Italien G, Sapra S.

Qual Life Res. 2014 Jun;23(5):1489-96. doi: 10.1007/s11136-013-0609-0. Epub 2013 Dec 31.

11.

Assessing health-related quality of life for advanced basal cell carcinoma and basal cell carcinoma nevus syndrome: development of the first disease-specific patient-reported outcome questionnaires.

Mathias SD, Chren MM, Colwell HH, Yim YM, Reyes C, Chen DM, Fosko SW.

JAMA Dermatol. 2014 Feb;150(2):169-76. doi: 10.1001/jamadermatol.2013.5870.

PMID:
24285085
12.

Use of the metastatic breast cancer progression (MBC-P) questionnaire to assess the value of progression-free survival for women with metastatic breast cancer.

Hurvitz SA, Lalla D, Crosby RD, Mathias SD.

Breast Cancer Res Treat. 2013 Dec;142(3):603-9. doi: 10.1007/s10549-013-2734-4. Epub 2013 Nov 12.

13.

Pain outcomes in patients with advanced breast cancer and bone metastases: results from a randomized, double-blind study of denosumab and zoledronic acid.

Cleeland CS, Body JJ, Stopeck A, von Moos R, Fallowfield L, Mathias SD, Patrick DL, Clemons M, Tonkin K, Masuda N, Lipton A, de Boer R, Salvagni S, Oliveira CT, Qian Y, Jiang Q, Dansey R, Braun A, Chung K.

Cancer. 2013 Feb 15;119(4):832-8. doi: 10.1002/cncr.27789. Epub 2012 Sep 5.

14.

The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.

Deuson R, Danese M, Mathias SD, Schoonen M, Fryzek J.

J Med Econ. 2012;15(5):956-76. doi: 10.3111/13696998.2012.688902. Epub 2012 May 23. Review.

PMID:
22533524
15.

Adaptation and validation of the Urticaria Patient Daily Diary for adolescents.

Mathias SD, Tschosik EA, Zazzali JL.

Allergy Asthma Proc. 2012 Mar-Apr;33(2):186-90. doi: 10.2500/aap.2012.33.3508.

PMID:
22525396
16.

Health-related quality of life in nonsplenectomized immune thrombocytopenia patients receiving romiplostim or medical standard of care.

Kuter DJ, Mathias SD, Rummel M, Mandanas R, Giagounidis AA, Wang X, Deuson RR.

Am J Hematol. 2012 May;87(5):558-61. doi: 10.1002/ajh.23163. Epub 2012 Mar 28.

17.

Evaluating the minimally important difference of the urticaria activity score and other measures of disease activity in patients with chronic idiopathic urticaria.

Mathias SD, Crosby RD, Zazzali JL, Maurer M, Saini SS.

Ann Allergy Asthma Immunol. 2012 Jan;108(1):20-4. doi: 10.1016/j.anai.2011.09.008. Epub 2011 Nov 2.

PMID:
22192960
18.

Pilot study of the effect of romiplostim on child health-related quality of life (HRQoL) and parental burden in immune thrombocytopenia (ITP).

Klaassen RJ, Mathias SD, Buchanan G, Bussel J, Deuson R, Young NL, Collier A, Bomgaars L, Blanchette V.

Pediatr Blood Cancer. 2012 Mar;58(3):395-8. doi: 10.1002/pbc.23312. Epub 2011 Sep 9.

PMID:
21910213
19.

Estimating minimally important differences for the worst pain rating of the Brief Pain Inventory-Short Form.

Mathias SD, Crosby RD, Qian Y, Jiang Q, Dansey R, Chung K.

J Support Oncol. 2011 Mar-Apr;9(2):72-8.

PMID:
21542414
20.

Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP).

Sanz MA, Aledort L, Mathias SD, Wang X, Isitt JJ.

Value Health. 2011 Jan;14(1):90-6. doi: 10.1016/j.jval.2010.10.017.

Supplemental Content

Loading ...
Support Center